BIIB

NASDAQ:BIIB

Biogen Inc.

Add to Watchlist
  • Stock

120.93

−0.12%

−7.07

USD last updated 01/08 02:13:39

Last Close

128.00

31/07 21:49

Market Cap

33.89B

Beta: 0.19

Volume Today

2.32M

Avg: 876.67K

PE Ratio

24.00

PFCF: 34.22

The report provides key insights into the global clinical trials landscape for Multiple Sclerosis, including data by region, phase, and sponsor. It identifies top drugs and trial trends to optimize strategies and enhance decision-making capabilities, covering prominent sponsors like Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, and IQVIA.

finance.yahoo.com

Biogen Inc. reported strong Q2 2025 financial results, surpassing earnings and revenue forecasts. The company's EPS of $5.47 exceeded expectations by 37.09%, with revenue reaching $2.6 billion versus a projected $2.32 billion. The stock rose 5.02% in pre-market trading, supported by a 75.65% gross profit margin and a 12.87 P/E ratio.

investing.com

The Central Nervous System (CNS) Therapeutics Market is projected to reach $208.5 billion by 2034, growing at a 6% CAGR. Key drivers include technological advancements, R&D investment, and rising demand for treatments for neurological disorders like Alzheimer's, Parkinson's, and chronic pain. The market is segmented by neurology (45%), psychiatry (35%), and pain management (20%), with North America leading due to advanced healthcare infrastructure and R&D funding. Emerging markets in Asia-Pacific, Latin America, and the Middle East are expected to grow rapidly due to increased healthcare access and innovation.

openpr.com

Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Biogen Inc. by 30.3%, owning approximately 187,803 shares valued at $25.7 million. Insider Rachid Izzar sold 2,223 shares, reducing his position by 25.99%. Biogen's stock fell 1.1% to $127.90, with analyst ratings averaging 'Hold' and a target price of $186.37. Multiple hedge funds adjusted their positions in Biogen, and the company reported Q1 earnings missing expectations. Biogen has a market cap of $18.56 billion and a 52-week stock range of $110.04 to $219.44.

marketbeat.com

Eisai and Biogen presented data on their investigational subcutaneous autoinjector (SC-AI) for lecanemab-irmb at the Alzheimer’s Association International Conference in Toronto. The results showed the SC-AI maintenance dose maintained clinical and biomarker benefits similar to the intravenous formulation after 18 months of initial treatment. Eisai’s stock has a beta of -0.18, indicating potential portfolio diversification benefits. The companies are co-commercializing lecanemab globally, with regulatory reviews ongoing in multiple countries. The article also covers Eisai’s fiscal year results, including projected operating profit and gross profit margin figures, alongside broader market context involving TSX and S&P 500 analysis.

ca.investing.com

    Description

    Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing EN...Show More

    Earnings

    Earnings per Share (Estimate*)

    2468102017-07-252019-07-232021-07-222023-07-252024-10-30

    Revenue (Estimate*)

    1B2B3B4B2017-07-252019-07-232021-07-222023-07-252024-10-30

    *Estimate based on analyst consensus